Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Revumenib
Syndax Pharmaceuticals
Acute Myeloid Leukemias
1 trial -
Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib
Syndax Pharmaceuticals
Newly Diagnosed AML with an NPM1 mutation
1 trial -
AXATILIMAB
Syndax Pharmaceuticals
Chronic graft versus host disease (cGVHD)
1 trial -
AXATILIMAB, Placebo
Syndax Pharmaceuticals
Idiopathic pulmonary fibrosis
1 trial -
Atezolizumab
Syndax Pharmaceuticals
Metastatic Cancer
1 trial -
Axatilimab
Syndax Pharmaceuticals
Chronic Graft-versus-host-disease
2 trials -
Axatilimab
Syndax Pharmaceuticals
Idiopathic Pulmonary Fibrosis
1 trial -
Azacitidine
Syndax Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
Durvalumab
Syndax Pharmaceuticals
Unresectable Intrahepatic Cholangiocarcinoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Metastatic Cholangiocarcinoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Melanoma
1 trial -
Entinostat
Syndax Pharmaceuticals
ER+ Breast Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals
Hodgkin's Lymphoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Renal Cell Carcinoma
2 trials -
Entinostat
Syndax Pharmaceuticals
Lymphoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Non-Small-Cell Lung Carcinoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Non Small Cell Lung Cancer
2 trials -
Fulvestrant
Syndax Pharmaceuticals
Breast Cancer
1 trial -
Pembrolizumab
Syndax Pharmaceuticals
Bladder Cancer
1 trial -
Pembrolizumab
Syndax Pharmaceuticals
Metastatic Uveal Melanoma
1 trial -
Revumenib
Syndax Pharmaceuticals
Acute Myeloid Leukemia
2 trials -
Revumenib
Syndax Pharmaceuticals
Relapsed Adult AML
1 trial -
Revumenib
Syndax Pharmaceuticals
Colorectal Cancer
1 trial -
Revumenib
Syndax Pharmaceuticals
Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources